NCT00814294已完成2 期
An 18-Week Randomized, Double-Blind, Multicenter, Comparator Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus
Diasome Pharmaceuticals0 个研究点目标入组 239 人开始时间: 2008年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 239
- 主要终点
- The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.
研究概览
简要总结
The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.
The secondary objectives are:
- To evaluate the effects of oral HDV-I versus placebo on the 7-point glucose test, fasting plasma glucose (FPG), insulin, homeostasis model assessment of insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β), frequency of hypoglycemic events, body weight, and lipid levels; and
- To evaluate the safety and tolerability of oral HDV-I.
详细描述
This is a multicenter, randomized, double-blind, placebo-controlled study with a washout/stabilization period of up to 12 weeks in duration and an 18-week double-blind treatment period. There will be a total of 8 visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 70 years, inclusive;
- •Diagnosis of type 2 diabetes mellitus;
- •Fasting plasma glucose <=250 mg/dL;
- •BMI <=45 kg/m2;
- •HbA1c levels as follows at Screening:
- •On a stable dose of metformin monotherapy with an HbA1c >=7.5% and <=9.5%;
- •On metformin and 1 other OAD (excluding TZD, exenatide, or insulin) with an HbA1c >=6.8% and <=9.0%;
- •Naïve to antidiabetic therapy or have not been on a stable dose of metformin monotherapy for <12 weeks with an HbA1c >=8.0% and <=10.5%;
- •Understanding of the study procedures and agreement to participate in the study, giving written informed consent;
- •Women may be enrolled if all of the following criteria (in addition to the above criteria) are met:
- •They are not pregnant (women of childbearing potential must have a negative serum pregnancy test at Visit 1);
- •They are not breast-feeding;
- •They do not plan to become pregnant during the study; and
- •They have had a hysterectomy or tubal ligation 6 months prior to the study, have been post-menopausal for 1 year, or will practice a method of birth control throughout the study.
排除标准
- •History of type 1 diabetes and/or history of ketoacidosis;
- •History of chronic (>2 months) use of insulin therapy or recent initiation of insulin use intended for chronic administration;
- •Use of TZD (pioglitazone or rosiglitazone) or exenatide within 3 months prior to Screening;
- •Use of prescription or over the counter weight loss agents within 1 month prior to Screening;
- •Use of any lipid-altering, antihypertensive, and other chronic use medication not stable for 1 month prior to Screening;
- •Use of any medication that may alter blood glucose analyses;
- •Any serious disorder including cardiac, pulmonary, hepatic, uncontrolled endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases that would interfere with the conduct of the study or interpretation of the data;
- •Require regular use of medication that interferes with the oral absorption and/or metabolism of insulin or metformin;
- •History of pancreatitis;
- •History of acquired immune deficiency syndrome or human immunodeficiency virus;
- •History of drug or alcohol abuse within the past 2 years;
- •Hospitalization for any cause within 14 days prior to the study;
- •History of an allergic or toxic response to oral HDV-I;
- •Uncontrolled hypertension: systolic blood pressure >160 mmHg and diastolic blood pressure >95 mmHg;
- •Triglycerides >400 mg/dL;
- •Aspartate aminotransferase or alanine aminotransferase >2.5 times the upper limit of normal (ULN);
- •Creatine phosphokinase >3 times the ULN;
- •Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within 4 weeks of starting the study;
- •Use of any investigational drug within 30 days preceding the first dose of study medication; or
- •Employment by the research center.
研究组 & 干预措施
1; Placebo
Placebo Comparator
Patients receive a sugar pill.
干预措施: placebo (Drug)
2; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
Experimental
Patients receive Oral HDV-Insulin (U-5).
干预措施: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5) (Drug)
3; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)
Experimental
Patients receive Oral HDV-Insulin (U-15).
干预措施: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15) (Drug)
结局指标
主要结局
The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.
时间窗: 18 weeks
次要结局
- To evaluate the effects of oral HDV-I versus placebo on the homeostasis model assessment of insulin resistance (HOMA-IR)and homeostasis model assessment of β-cell function (HOMA-β)(18 Weeks)
- To evaluate the effects of oral HDV-I versus placebo on frequency of hypoglycemic events, body weight, and lipid levels(18 Weeks)
- To evaluate the effects of oral HDV-I versus placebo on the 7-point glucose test(18 weeks)
- To evaluate the effects of oral HDV-I versus placebo on fasting plasma glucose (FPG) and insulin(18 weeks)
研究者
相似试验
已完成
3 期
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00885378AstraZeneca166
已完成
3 期
A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on MetforminType 2 Diabetes MellitusNCT02794792Astellas Pharma Europe B.V.268
终止
4 期
Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary CareDiabetes Mellitus, Type 2NCT00950534Sanofi25
已完成
2 期
Heart Failure and AnemiaHeart FailureAnemiaNCT00049985Amgen300
已完成
3 期
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin AlfaSmall Cell Lung CancerNCT00119613Amgen600